Orally administrable composition capable of providing enhanced bioavailability when ingested
US6054136A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Apr 11, 1997 |
| Grant date | Apr 25, 2000 |
| Priority date | — |
| Expiry date | Apr 11, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2800/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Composition for pharmaceutical or cosmetic use, capable of forming a microemulsion, comprising at least: PA1 an active principle, PA1 a lipophilic phase consisting of a mixture of fatty acid esters and glycerides, PA1 a surfactant (SA), PA1 a cosurfactant (CoSA), PA1 a hydrophilic phase, characterized: PA1 in that the lipophilic phase consists of a mixture of C.sub.8 to C.sub.18 polyglycolized glycerides having a hydrophilic-lipophilic balance (HLB) of less than 16, this lipophilic phase representing from 30 to 75% of the total weight of the composition; PA1 in that the surfactant (SA) is chosen from the group comprising saturated C.sub.8 -C.sub.10 olyglycolized glycerides and oleic esters of polyglycerol, this surfactant having an HLB of less than 16; PA1 in that the cosurfactant (CoSA) is chosen from the group comprising lauric esters of propylene glycol, oleic esters of polyglycerol and ethyl diglycol; PA1 in that the SA/CoSA ratio is between 0.5 and 6; PA1 and in that the hydrophilic phase of the final microemulsion is supplied after ingestion by the physiological fluid of the digestive milieu.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.